Compare Firy Inc. (FIRY) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Cassava Sciences Inc — how do they compare? Firy Inc. trades at $12.25 (market cap $199.80M), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: Firy Inc. is far larger — about 5.1× Cassava Sciences Inc's market cap, and Firy Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Cassava Sciences Inc for 37 Days on average.
| FIRY | FLNA | |
|---|---|---|
Market Cap | $199.80M | $39.40M |
Volume | 92,993 | 759,018 |
Sector | Technology | Health |
52-Week High | $13.10 | $4.64 |
52-Week Low | $2.28 | $0.68 |
Typical Hold Time | 13 Days | 37 Days |
Enterprise Value | $168.40M | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $11.85, down 5.05% today, with a bullish technical signal from moving averages despite negative fundamental metrics. The company reported Q2 2026 revenue of $31.0 million but missed EPS expectations with a net loss. Recent developments include a $719 million legal victory against Papaya Gaming and the appointment of Marc Lasry to the board, though cash burn remains elevated at -$86.41M for 2025.
The outlook remains challenged by persistent losses and negative margins, but potential collection of the legal judgment could provide significant upside. Risks include execution on cost controls and uncertainty around Papaya Gaming debt settlement. Analyst sentiment is mixed with 20% buy ratings amid high volatility.
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
